Aptose Biosciences Inc. Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Jan 10, 2025 · CIK: 882361
| Field | Detail |
|---|---|
| Company | Aptose Biosciences INC. (APTOF) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, exhibits, regulatory
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Jan 10th for Jan 9th events, including Reg FD disclosure & exhibits.
AI Summary
Aptose Biosciences Inc. filed an 8-K on January 10, 2025, reporting events as of January 9, 2025. The filing is a Regulation FD Disclosure and includes Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc., is incorporated in Canada and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides updated information and exhibits for Aptose Biosciences Inc., which is crucial for investors to stay informed about the company's regulatory and financial status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for disclosures and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- January 9, 2025 (date) — Earliest event reported date
- January 10, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, and includes a Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 9, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed as of January 10, 2025.
What were Aptose Biosciences Inc.'s former names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc., which was formerly known as Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-01-10 07:00:11
Filing Documents
- f8k_010825.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-000151.txt ( ) — 221KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_010825_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On January 9, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated January 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: January 9, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer